Condition: Mastocytosis, Systemic · Sponsor: Blueprint Medicines Corporation
The primary objective of the rollover study is to evaluate the long-term safety of avapritinib in participants who have completed a Blueprint Medicines sponsored study (parent study) and continued to benefit from avapritinib.
This description comes directly from the study's public registry record.
Blueprint Medicines · 617-714-6707 · MedInfo@blueprintmedicines.com
Always discuss trial participation with your own doctor first.
| Universitair Ziekenhuis Antwerpen (UZA) | Edegem, Belgium | Recruiting |
| The Hospital for Sick Children | Toronto, Ontario, Canada | Recruiting |
| A.O.U. San Giovanni di Dio e Ruggi d'Aragona di Salerno | Salerno, Italy | Recruiting |
| Universitair Medisch Centrum Groningen | Groningen, Netherlands | Recruiting |
| Erasmus Medisch Centrum | Rotterdam, Netherlands | Recruiting |
| Oslo University Hospital | Oslo, Norway | Recruiting |
| Guys and St Thomas NHS Foundation Trust - St Thomas Hospital | London, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06748001